# Performance evaluation of the point-of-care SAMBA II SARS-CoV-2 Test for detection of SARS-CoV-2

Sonny M Assennato[a*], Allyson V Ritchie[a*], Cesar Nadala[b], Neha Goel[a], Hongyi Zhang[c], Rawlings Datir[d], Ravindra K Gupta[e,f], Martin D Curran[c**], Helen H Lee[a,b**#]

*Assennato and Ritchie contributed equally

**Curran and Lee contributed equally

a. Diagnostics for the Real World EU Ltd., Chesterford Research Park, Great Chesterford, UK

b. Diagnostics for the Real World Ltd., San Jose, USA

c. Public Health England, Clinical Microbiology and Public Health Laboratory, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK

d. Division of Infection and Immunity, University College London, London, UK

e. Department of Medicine, University of Cambridge, Cambridge, UK

f. Africa Health Research Institute, Durban, South Africa

**Running Title:** SAMBA II SARS-CoV-2 analytical and clinical evaluation

# Address correspondence to Dr Helen H Lee, email: hl207@cam.ac.uk

**Key words:** SAMBA II, SARS-CoV-2, point-of-care, COVID-19

**Abstract**

Nucleic acid amplification for the detection of SARS-CoV-2 RNA in respiratory samples is the standard method for diagnosis. These tests are centralised and therefore turnaround times can be 2-5 days. Point-of-care testing with rapid turnaround times would allow more effective triage in settings where patient management and infection control decisions need to be made rapidly.

Inclusivity and specificity of the SAMBA II SARS-CoV-2 assay was determined by *in silico* analyses of the primers and probes. Analytical and clinical sensitivity and specificity of the SAMBA II SARS-CoV-2 Test was evaluated for analytical sensitivity and specificity. Clinical performance was evaluated in residual clinical samples compared to the Public Health England reference tests.

The limit of detection of the SAMBA II SARS-CoV-2 Test is 250 cp/mL and is specific for detection of 2 regions of the SARS-CoV-2 genome. The clinical sensitivity was evaluated in 172 clinical samples provided by Public Health England, Cambridge, which showed a sensitivity of 98.9% (95% CI 94.03-99.97%), specificity of 100% (95% CI 95.55-100%), PPV of 100% and NPV of 98.78% (92.02-99.82%) compared to testing by Public Health England (PHE). SAMBA detected 3 positive samples that were initially negative by PHE.

The data shows that the SAMBA II SARS-CoV-2 Test performs equivalently to the centralised testing methods with a much quicker turnaround time. Point of care testing, such as SAMBA, should enable rapid patient management and effective implementation of infection control measures.

## Introduction

The SARS-CoV-2 was first reported in Wuhan, China, in early December 2019 and is the causative agent of coronavirus disease 19 (COVID-19) [1]. It has since spread to over 188 countries/regions around the world [2], causing 317,234 deaths [3]. It was declared a pandemic by the World Health Organisation on the 11th of March 2020 [4]. In Europe, the country with the highest number of deaths is UK, which as of the 17th of May has had 243,694 lab-confirmed cases and 34,636 deaths in all settings [5].

Nucleic acid testing is essential for early diagnosis of SARS-CoV-2 infection as antibody response is often not detected until 7-10 post onset of symptoms [6]. Upper respiratory tract (URT) specimens such as nose and throat swabs generally have high SARS-CoV-2 viral loads upon symptom onset [7]. The standard diagnostic test for SARS-CoV-2 in the UK is done by real-time RT-PCR of the RdRp gene [8], from a combined throat and nose swab sample. The UK has dramatically scaled up testing from 5,000 tests per day in March 2020 to 100,000 tests per day by the end of April. Although this test has good accuracy, the samples must be transported to centralized testing laboratories and batched for processing, which leads to turnaround times of around 48 hours or more. This means treatment of severely ill patients may be suboptimal when other causative pathogens are in the differential diagnosis and those requiring admission or triage with possible COVID-19 maybe unnecessarily isolated or inappropriately cohorted in a COVID-19 ward. This causes obvious bottlenecks in addition to the sheer number of samples that require processing; at present hospital and regional laboratories are at full capacity and a rapid point of care (POC) testing is required.

The SAMBA II nucleic acid testing system was originally designed for HIV testing in

76 POC and resource-limited settings, with CE-marked products for early infant diagnosis
77 [9,10] and viral load monitoring [11-13]. Since 2017, SAMBA HIV tests have been
78 implemented in Uganda, Malawi, Zimbabwe and Central African Republic. The
79 SAMBA II SARS-CoV-2 Test system has now been developed to specifically detect
80 the presence of the novel coronavirus, SARS-CoV-2, in nose and throat swab samples
81 run on the SAMBA II instrument. Test results are available in approximately 1.5 hours.
82 We have here assessed the analytical and clinical performance of the SAMBA II
83 SARS-CoV-2 Test using panels and clinical samples.
84

85 **Materials and Methods**

86 **SAMBA sample preparation, amplification, and detection**

87 For the SAMBA II system, sample preparation, amplification, and detection as well as
88 reading and interpretation of the results are fully automated. The test is carried out in
89 the SAMBA II Assay Module under the control of the SAMBA II Tablet Module as
90 previously described for HIV [9-12], according to the manufacturer's instructions for
91 use. Nose and throat swab samples are preferably resuspended in 2 mL of SAMBA
92 SCoV buffer but the system can be used with viral transport medium (VTM) if the
93 sample is diluted 1:2 with SCoV buffer prior to processing. The input volume for the
94 SAMBA test is 300 μl of which 250 μl is used by the SAMBA II machine as input into
95 the sample preparation. The SAMBA II SARS-CoV-2 Test specifically amplifies and
96 detects two regions of the SARS-CoV-2 genome in the ORF1ab (region 1) and
97 nucleocapsid protein (region 2), reported as two distinct lines on the test strip. A third
98 line on the test strip, the internal control, is present to control for false negatives
99 caused by instrument/reagent problems or inhibition. The presence of one or both test
100 lines indicates a positive result. The presence of just the internal control line indicates

101 a negative result.

102 **Virus inactivation in SAMBA SCoV buffer**

103 SAMBA SCoV buffer, containing Triton x100, is provided with the SAMBA II SARS-
104 CoV-2 Test for sample collection of the nose and throat swabs. Single round of VSV-
105 G pseudotyped lentiviruses were produced by transfecting HEK-293T cells in a 3-
106 plasmid transfection system (HIV Gag-pol expresser under a CMV promoter,
107 luciferase genome reporter and VSV-g envelope) as previously described [14]. Virus
108 supernatant was harvested after 24 hours and filtered. Fifty (50) µL
109 of pseudovirus preparation was added to increasing dilutions of SAMBA SCoV Buffer
110 in duplicates and incubated at room temperature for 5 minutes. 100µL of the virus-
111 reagent prep was then used to infect $1.0 \times 10^6$ TZMbl target cells per well in a 96-well
112 plate and incubated at 37$^o$C, 5% $CO_2$. Forty-eight (48) hours post-infection, luciferase
113 expression was measured using SteadyGlo and a Glomax Luminometer (both
114 Promega).

115

116 ***In silico* inclusivity analysis**

117 The SAMBA-SARS-CoV-2 primers and probes for Orf1ab and N regions were
118 individually evaluated using *in-silico* analysis with respect to 157 SARS-CoV-2
119 sequences in the NCBI database.

120

121 ***In silico* specificity analysis**

122 *In silico* analysis for possible cross-reactions with related human Coronaviruses
123 (Human coronavirus 229E, Human coronavirus OC43, Human coronavirus HKU1,
124 Human coronavirus NL63, SARS-coronavirus and MERS-coronavirus) was conducted

125 by mapping primers in the SAMBA II SARS-CoV-2 Test individually to the sequences
126 downloaded from the NCBI database.
127 An *in silico* analysis for possible cross-reactions with other high-priority organisms was
128 conducted by carrying out a blastn search for each of the SAMBA primers and probes
129 against NCBI databases and retrieving all sequences with homologies > 80%.
130

131 **Panels and samples**

132 Panel members for determination of the limit of detection (LOD) were prepared by
133 making serial dilutions of SARS-CoV-2 RNA from strain 2019-nCoV/Italy-INMI1 from
134 EVAg (code number: 008N-03894) in pooled negative combined nose and throat
135 swab samples to target concentrations of 750, 500, 250, 200, 150 and 100
136 copies/mL.
137 A Coronavirus RNA specificity panel containing hCoV-NL63, hCoV-229E, hCoV-
138 OC43, MERS-CoV and SARS-CoV HKU339849 were sourced from EVAg (code
139 number 011N-03868). RNA samples from this panel were tested at >100,000 cp/test
140 in the SAMBA II test to determine specificity against other human Coronaviruses.
141

142 **Contrived clinical samples**

143 Combined nose and throat swabs were collected from 35 presumed negative
144 individuals using FLOQSwabs (Copan, Italy) and SAMBA SCoV buffer. Thirty
145 contrived positive clinical samples were prepared by spiking known concentrations of
146 SARS-CoV-2 RNA strain 2019-nCoV/Italy-INMI1 (EVAg, Italy) into individual negative
147 specimens to produce final concentrations of 1x LoD (n=3), 2x LoD (n=17), 3x LoD
148 (n=5), 5x LoD (n=3) and 100x LoD (n=2).
149

150 **Clinical evaluation**

151 The clinical performance of the SAMBA II SARS-CoV-2 Test was further evaluated
152 retrospectively with 172 residual blinded combined nose and throat swab samples
153 from Public Health England (PHE), Cambridge laboratory. These residual samples
154 were from symptomatic individuals with suspected Covid-19 from around the East of
155 England region sent for routine laboratory diagnosis and provided as VTM diluted 1:2
156 with SAMBA SCoV buffer. In total 172 samples were tested by the SAMBA II SARS-
157 CoV-2 Test and results were compared to the Cambridge RdRp gene (Wuhan) assay
158 on the Rotor gene Q real-time PCR assay routinely used by Public Health England
159 Cambridge Laboratory based on the publication by Sridhar et al., 2020 [15]. Results
160 are expressed as positive or negative with a Ct cut off of 36 for positive results.
161 Samples were also tested with the PHE Colindale (Reference Laboratory) assay,
162 based on the publication by Corman et al, 2020 [8], which amplifies a different region
163 of the RdRp gene.

164 For LOD, we used SARS-CoV-2 RNA quantified in cp/mL but in the clinical samples,
165 SAMBA II results were compared to real-time PCR results expressed as Ct number
166 (number of cycles). By systematically testing serial dilutions of samples calibrated in
167 cp/mLby the PHE test a correspondence curve was drawn showing for instance that
168 25 Ct corresponded to 100,000 cp/mL and 30 Ct to 1,000 cp/mL. The curve obtained
169 is added as supplementary information.

170

171 **Research Ethics**

172 Surplus samples obtained from patients known to be symptomatic for COVID-19 and
173 submitted to the Public Health England Cambridge Laboratory for routine testing were
174 retrieved before being discarded. These samples were rendered anonymous and

175 provided blinded for the purpose of test validation. Public Health England and NHS
176 Research Ethics Committee have permitted the use of residual samples in this
177 manner, strictly for the purpose of diagnostic assay validation [16]. The evaluation was
178 carried out in accordance with The Use of Human Organs and Tissue act [17].
179
180 **Results**
181 **Viral inactivation by SAMBA SCoV collection buffer**
182 Due to the highly infectious nature of SARS-CoV-2, a proprietary buffer which has a
183 low pH and a strong detergent was developed for the SAMBA SARS-CoV-2 Test for
184 sample collection. The ability of the SAMBA SCoV Buffer to inactivate pseudoviruses
185 was assessed by incubating pseudoviruses with increasing dilutions of
186 SAMBA SCoV Buffer in duplicates at room temperature for 5 minutes. Forty-eight (48)
187 hours post-infection, luciferase expression was measured. Figure 1 shows the plot of
188 $\log_{10}$ relative light units (RLU) of luciferase expression vs concentration of
189 SAMBA SCoV Buffer containing Triton X100. Results show that luciferase activity was
190 insignificant up to 1:128 dilution of the SAMBA SCoV Buffer, indicating that
191 the pseudovirus was inactivated after 5-minute exposure at room temperature (Figure
192 1). For the SAMBA II Test, a 10-minute soaking of the swab in the
193 SAMBA SCoV Buffer is recommended.
194
195 **Limit of detection**
196 The limit of detection (LOD) of the SAMBA II SARS-CoV-2 Test was determined using
197 serial dilutions of SARS-CoV-2 RNA in pooled negative combined nose and throat
198 swab samples. The initial LOD was determined by testing 6 levels at target
199 concentrations of 750, 500, 250, 200, 150 and 100 copies/mL. Each panel member

200 was tested in replicates of 3 (Table 1). The final LOD was confirmed by testing 250
201 copies/mL in replicates of 20, of which all were detected. The results are summarized
202 in Table 1. Therefore, the claimed LOD of the SAMBA II SARS-CoV-2 Test is 250
203 cp/mL.
204
205 **Inclusivity**
206 The SAMBA II SARS-CoV-2 Test primers and probes for Target 1 (Orf 1ab) had 100%
207 match to all but one available SARS-CoV-2 sequence for this region in the NCBI
208 database (n=157). For this one sequence, a single nucleotide mismatch was found
209 that maps to the capture probe with no predicted impact on the assay performance.
210 The primers and probes for Target 2 (N) had 100% identity to all available SARS-CoV-
211 2 sequences for this region in the NCBI database (n=157).
212
213 **Specificity analysis**
214 *In silico* analysis for possible cross-reactions with related human coronaviruses
215 (Human coronavirus 229E, Human coronavirus OC43, Human coronavirus HKU1,
216 Human coronavirus NL63, SARS-coronavirus and MERS-coronavirus) concluded that
217 none of the SAMBA primers had >80% homology to the organisms listed. In addition
218 to *in silico* analysis, the SAMBA II SARS-CoV-2 Test was evaluated for specificity by
219 using >100,000 cp/test of hCoV-NI63, hCoV-229E, hCoV-OC43, MERS-CoV and
220 SARS-CoV RNA as target in the assay. All samples gave negative results in SAMBA
221 showing that both the Orf1ab and N primers and probes in the SAMBA II SARS-CoV-
222 2 were specific.
223 An *in silico* analysis for possible cross-reactions with other high-priority organisms
224 showed that only one SAMBA probe (N region) had greater than 80% homology (81%)

225 to one of the high priority organisms (*Pneumocystis jirovecii* [PJP]). This marginal
226 homology would not impact the performance of the test because the other primers and
227 probes have no homology to *P. jirovecii*. This homology would not be able to compete
228 with 100% homology of the SARS-CoV-2 amplicon to the capture probe.
229
230 **Contrived clinical specimens**
231 Positive (n=30) and negative (n=35) swab samples were contrived from individual
232 nose and throat swab samples collected from 35 individuals and tested with the
233 SAMBA II SARS-CoV-2 Test. Spiked positive samples were tested at 1x LOD (n=3),
234 2x LOD (n=17), 3x LOD (n=5), 5x LOD (n=3) and 100x LOD (n=2) by spiking SARS-
235 CoV-2 RNA into individual negative swab samples. All 35 negative samples were
236 negative and all 30 spiked positive samples were positive when tested with the
237 SAMBA II SARS-CoV-2 Test (Table 2). The overall sensitivity was 100% (95%CI:
238 88.43-100%) and specificity was 100% (95%CI: 90-100%).
239
240 **Clinical evaluation**
241 The clinical performance of the SAMBA II SARS-CoV-2 Test was further evaluated
242 with 172 combined nose and throat samples from symptomatic individuals provided
243 blinded by Public Health England (PHE), Cambridge. The samples were provided in
244 Viral Transport Medium (VTM) diluted 1:2 with SAMBA SCoV buffer. After initial testing
245 there were 87 concordant positives, 81 concordant negatives and 4 discrepant results
246 (3 SAMBA positive and one SAMBA negative) compared with the PHE Colindale
247 reference laboratory test (Table 3). The three SAMBA positive samples were repeat
248 positive by SAMBA and on retest by PHE they were found to be borderline positive
249 with high CT values for at least one of the target genes on the Colindale or Cambridge

250 (Wuhan) test (Table 4). The one SAMBA negative sample was negative on repeat by
251 SAMBA but was positive by PHE for RdRp using both the Cambridge (Wuhan) and
252 Colindale assays, with Ct values of 28.87 and 31.18 respectively (Table 4). Therefore,
253 there was just 1 discrepant sample after retest, a false negative for SAMBA (Table 5).
254 From this data set the SAMBA II SARS-CoV-2 Test has a sensitivity of 98.9% (95%
255 CI 94.03-99.97%), specificity of 100% (95% CI 95.55-100%), PPV of 100% and NPV
256 of 98.78% (92.02-99.82%) when compared to the PHE reference tests. The one
257 SAMBA false negative gave a high Ct value on the PHE test (>31), suggesting low
258 viral load, and it was diluted (1:2) for SAMBA testing, which may explain the false-
259 negative result.
260

261 **Discussion**

262 POC molecular tests for SARS-CoV-2, such as SAMBA II, are required to quickly
263 triage patients as centralised testing can take 2-5 days for results. In addition, POC
264 tests would be extremely useful for non-laboratory residential settings such as prisons,
265 immigration centres, nursing homes and rehabilitative centres. The people living in
266 such facilities tend to be vulnerable populations who are at a higher risk for adverse
267 outcome and for infection due to living in close proximity to others [18] and early
268 identification and implementation of increased infection control measures would
269 reduce spread amongst residents and staff. POC would also be extremely useful in
270 other situations where rapid and accurate results are required e.g organ donation,
271 hospital admissions and emergency surgery. POC molecular tests with rapid
272 turnaround, such as SAMBA II, will be essential not only during high rates of infection
273 but also as the country begins to end the lockdown period and localised outbreaks will
274 need to be managed quickly and efficiently.

275 Our data shows that the SAMBA II SARS-CoV-2 Test is equivalent to centralised
276 testing with excellent sensitivity and specificity. Samples are inactivated in the SAMBA
277 collection buffer and results are available within 86-101 minutes at the POC. High
278 sensitivity and specificity are essential for the appropriate triaging and treatment of
279 incoming patients. The assay has a limit of detection of 250 cp/mL, which is in-line
280 with that claimed by other commercial SARS-CoV-2 tests [19,20]. The specificity of
281 the SAMBA SARS-CoV-2 Test in clinical samples was 100% and the sensitivity was
282 98.9% compared to the centralised molecular testing by PHE. This data includes 3
283 positive samples detected by SAMBA that were original negative by centralised testing
284 indicating good sensitivity. Clinical evaluation by Zhen et al [21] comparing the
285 performance of Xpert® Xpress SARS-CoV-2 (Cepheid), ePlex® SARS-CoV-
286 2 (GenMark) and ID NOW™ COVID-19 (Abbott) showed limit of detection of 100
287 cp/mL, 1,000 cp/mL and 10,000 cp/mL and clinical agreement with the reference
288 standard of 98.3%, 91.4% and 87.7% respectively. In another study the Xpert system
289 has been shown to have good agreement with the reference test over a wide range of
290 Ct values, including low positives [22,23] with a positive agreement of 98.9% and
291 negative agreement of 92.0% compared to Roche cobas [22]. The Abbott ID NOW
292 has been shown to have a positive agreement of 73.9% (95% CI: 63.2-82.3%) and
293 negative agreement of 100% (95%CI: 92.9-100%) compared to the lab-based Roche
294 cobas system, with the majority of false negative samples being low viral load (>30 Ct
295 cycles by Roche cobas) [22]. Abbott have since modified the instructions for use to
296 remove the use of swab in transport medium as samples may become too dilute and
297 affect the sensitivity [24].
298 Potential limitations of this study include that the virus inactivation study was carried
299 out using a constructed pseudovirus rather than a SARS-CoV-2 or other coronavirus

300 due to availability. Also clinical samples were collected in VTM and diluted 1:2 in SCoV
301 buffer rather than collected directly into SCoV buffer, which may affect the sensitivity.
302

303 **Acknowledgements**

304 RKG is funded by Wellcome Senior Fellowship In Clinical Science award no WT108082AIA

305

306 **References**

307 1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X,
308 Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H,
309 Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. 2020. Clinical
310 features of patients infected with 2019 novel coronavirus in Wuhan, China.
311 Lancet 395(10223):497-506.
312 2. COVID-19 Dashboard by the Center for Systems Science and Engineering
313 (CSSE) at John Hopkins University (JHU). ArcGIS. John Hopkins University.
314 (Accessed 18th May 2020).
315 3. https://www.worldometers.info/coronavirus/ (Accessed 18th May 2020).
316 4. World Health Organisation. 2020. WHO Director-General's opening remarks at
317 the media briefing on COVID-19 - 11 March 2020. Available from:
318 https://www.who.int/dg/speeches/detail/who-director-general-s-opening-
319 remarks-at-the-media-briefing-on-covid-19---11-march-2020. (Accessed 10th
320 May 2020)
321 5. https://coronavirus.data.gov.uk (Accessed 18th May 2020).
322 6. Grzelak L, Temman S, Plachais C, Grzelak L, Temmam S, Planchais C,
323 Demeret C, Huon C, Guivel F, Staropoli I, Chazal M, Dufloo J, Planas
324 D, Buchrieser J, Rajah MM, Robinot R, Porrot F, Albert M, Chen K,

325 Crescenzo B, Donati F, Anna F, Souque P, Gransagne M, Bellalou J,
326 Nowakowski M, Backovic M, Bouadma l, Le Fevre L, Le Hingrat
327 Q, Descamps D, Pourbaix A, Yazdanpanah Y, Tondeur L, Besombes C,
328 Ungeheuer M, Mellon G, Morel P, Rolland S, Rey F, Behillil S, Enouf
329 V, Lemaitre A, Creach M, Petres S, Escriou N, Charneau P, Fontanet A, Hoen
330 B, Bruel T, Eloit M, Mouquet H, Schwartz O, van der Werf S. 2020. SARS-
331 CoV-2 serological analysis of COVID-19 hospitalized patients, pauci-
332 symptomatic individuals and blood donors. medRxiv
333 https://doi.org/10.1101/2020.04.21.20068858
334 7. Pan Y, Zhang D, Yang P, Poon LIM, Wang Q. 2020. Viral load of SARS-CoV-2
335 in clinical samples. The Lancet. 20(4):411-412.
336 8. Corman, VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DKW, Bleicker
337 T, Brnink S, Schneider J, Schmidt ML, Mulders DGJC, Haagmans BL, van der
338 Veer B, van den Brink S, Wijsman L, Goderski G, Romette J-L, Ellis J, Zambon
339 M, Peirlis M, Goossens H, Reusken C, Koopmans MPG, Drosten C. 2020.
340 Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro
341 Surveill, 25(3) https://doi.org/10.2807/1560-7917.ES.2020.25.3.2000045
342 9. Ritchie AV, Goel N, Sembongi H, Lehga J, Farleigh LE, Edemaga D,
343 Wisniewski CA, Lee HH.(2016. Performance evaluation of the point-of-care
344 SAMBA I and II HIV-1 Qual whole blood tests. J Virol Methods. Nov;237:143-
345 149.
346 10. Ondiek J, Namukaya Z, Mtapuri-Zinyowera S, Balkan S, Elbireer A, Ushiro
347 Lumb I, Kiyaga C, Goel N, Ritchie A, Ncube P, Omuomu K, Ndiege K,
348 Kekitiinwa A, Mangwanya D, Fowler MG, Nadala L, Lee H. 2017. Multi-
349 country validation of SAMBA – A novel molecular point-of-care test for HIV-1

350 detection in resource-limited setting. J Acquir Immune Defic Syndr. Oct
351 1;76(2):e52-e57.
352 11. Ritchie AV, Ushiro-Lumb I, Edemaga D, Joshi HA, De Ruiter A, Szumilin E,
353 Jendrulek I, McGuire M, Goel N, Sharma PI, Allain JP, Lee HH. 2014. SAMBA
354 HIV semiquantitative test, a new point-of-care viral-load-monitoring assay for
355 resource-limited settings. J Clin Microbiol. 52(9):3377-83.
356 12. Goel N, Ritchie AV, Mtapuri-Zinyowera S, Zeh C, Stepchenkova T, Lehga J,
357 De Ruiter A, Farleigh LE, Edemaga D, So R, Sembongi H, Wisniewski C,
358 Nadala L, Schito M, Lee H. 2017. Performance of the SAMBA I and II HIV-1
359 Semi-Q Tests for viral load monitoring at the point-of-care. J Virol Methods.
360 Jun;224:39-45.
361 13. Titchmarsh L, Zeh, C, Verpoort T, Allain, J-P and Lee, H.2015. Leukodepletion
362 as a Point-of-Care Method for Monitoring HIV-1 Viral Load in Whole Blood. J. Clin.
363 Microbiol.53(4):1080-1086.
364 14. Gupta RK, Kohli A, McCormick AL, Towers GJ, Pillay D, Parry CM. 2017 Full
365 length HIV-1 Gag determines protease inhibitor susceptibility within *in*
366 *vitro* assays. AIDS. Jul17;24(11):1615-1655.
367 15. Sridhar S, Forrest S, Kean I, Young J, Scott JB, Maes M, Pereira-Dias J,
368 Parmar S, Routledge M, Rivett L, Dougan G, Weekes M, Curran M,
369 Goodfellow I, Baker S. 2020. A blueprint for the implementation of a
370 validated approach for the detection of SARS-Cov2 in clinical samples in
371 academic facilities. bioRxiv https://doi.org/10.1101/2020.04.14.041319
372 16. Public Health England. 2017. UK Standards for Microbiology
373 Investigations - Evaluations, validations and verifications of diagnostic tests.
374 Issue no. 5, 16 March 2017

375 17. UK Legislation. Human Tissue Act. 2004.
376 18. Infection Prevention and Control guidance for Long-Term Care Facilities in the
377 context of COVID-19: World Health Organisation. [updated 21 March 2020].
378 Available from: https://apps.who.int/iris/handle/10665/331508. (Accessed 11
379 May 2020).
380 19. FDA. 2020. Xpert® Xpress SARS-CoV-2 Instructions for Use, April 2020.
381 https://www.fda.gov/media/136314/download (Accessed 10 May 2020).
382 20. FDA. 2020. Biomerieux ARGENE® SARS-CoV-2 R Gene® Instructions for
383 Use, May 2020. https://www.fda.gov/media/137742/download (Accessed 10
384 May 2020).
385 21. Zhen W, Smith E, Manj R, Schron D, Berry GJ. (2020) Clinical Evaluation of
386 Three Sample-To-Answer Platforms for the Detection of SARS-CoV-2. J. Clin.
387 Microbiol. Apr 24 DOI: 10.1128/JCM.00783-20
388 22. Smithgall MC, Scherberkova' I, Whittier S, Green DA (2020) Comparison of
389 Cepheid Xpert Xpress and Abbott ID Now to Roche cobas for the Rapid
390 Detection of SARS-CoV-2. bioRxiv https://doi.org/10.1101/2020.04.22.055327.
391 23. Moran A, Beavis KG, Matushek SM, Ciaglia C, Francios N, Tesic V, Love N.
392 2020. The Detection of SARS-CoV-2 using the Cepheid Xpert Xpress SARS-
393 CoV-2 and Roche cobas SARS-CoV-2 Assays. J Clin Microbiol. Apr 17.
394 doi: 10.1128/JCM.00772-2
395 24. Abbott. 2020. ID NOW COVID-19 Technical Brief and Sample Type Labelling
396 Update. April 2020

397 **Figure 1. Viral inactivation as demonstrated by Luminescence from a VSV-G**
398 **pseudotyped reporter virus in descending concentrations of SAMBA Reagent**
399 **(SCoV Buffer).**




400

401

402

403 **Table 1. LOD of the SAMBA II SARS-CoV-2 Test**

| Concentration SARS-CoV-2 RNA (cp/mL) | Number tested | Number positive | % positive |
|---|---|---|---|
| 750 | 3 | 3 | 100 |
| 500 | 3 | 3 | 100 |
| **250** | **20** | **20** | **100** |
| 200 | 3 | 2 | 66.7 |
| 150 | 3 | 2 | 66.7 |
| 100 | 3 | 0 | 0 |

404

405

406

407 **Table 2. Clinical performance in 65 contrived clinical samples**

| Concentration SARS-CoV-2 RNA (cp/mL) | Number tested | Number positive | % agreement (95% CI) |
|---|---|---|---|
| 1-2x LOD | 20 | 20 | 100% (86.1-100%) |
| ≥3x LOD | 10 | 10 | 100 % (74.1-100%) |
| Negative | 35 | 0 | 100% (91.5-100%) |

408

409 **Table 3. Clinical performance in 172 clinical samples compared to PHE**

410 **reference test (initial results)**

| | | PHE reference test | |
|---|---|---|---|
| | | **POSITIVE** | **NEGATIVE** |
| **SAMBA SARS-CoV-2 Test** | **POSITIVE** | 87 | 3 |
| | **NEGATIVE** | 1 | 81 |

411

412

413

414

415

416 **Table 4. Discrepant analysis of 4 samples**

| Sample ID | SAMBA | | PHE Colindale assay RdRp | | PHE Wuhan Cambridge assay | | Final result |
|---|---|---|---|---|---|---|---|
| | Initial result | Repeat result | Initial (Ct) | Repeat (Ct) | RdRp (Ct) | E (Ct) | |
| 1-25 | NEG | NEG | POS (31.18) | Not tested | POS (28.87) | Not tested | POS |
| 2-17 | POS | POS | NEG | NEG | NEG | POS (34.99) | POS |
| 2-25 | POS | POS | NEG (36.58) | POS (33.62) | NEG | NEG | POS |
| 2-38 | POS | POS | NEG | NEG | POS (35.09) | POS (34.06) | POS |

417

418

419 **Table 5. Clinical performance in 172 clinical samples compared to PHE**

420 **reference test (after retest)**

| | | PHE reference test | |
|---|---|---|---|
| | | POSITIVE | NEGATIVE |
| SAMBA SARS-CoV-2 Test | POSITIVE | 90 | 0 |
| | NEGATIVE | 1 | 81 |

421